Technical Analysis for CBLI - Cleveland BioLabs, Inc.

Grade Last Price % Change Price Change
grade F 1.1 6.80% 0.07
CBLI closed up 6.8 percent on Thursday, September 19, 2019, on 46 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical CBLI trend table...

Date Alert Name Type % Chg
1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
Boomer Sell Setup Bearish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
1,2,3 Retracement Bearish Bearish Swing Setup 6.80%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 6.80%
Calm After Storm Range Contraction 6.80%
Wide Bands Range Expansion 6.80%
Oversold Stochastic Weakness 6.80%

Older signals for CBLI ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Cleveland BioLabs, Inc., a clinical-stage biotechnology company, engages in the research, development, and commercialization of products that have the potential to treat cancer, reduce death from total body irradiation, and counteract the genotoxic effects of radio- and chemotherapies for oncology patients. Its lead drug is Entolimod, which is being developed for radiation countermeasure and cancer treatment. The company's products candidates also include CBL0102, which is undergoing a Phase I safety and tolerability study in patients with liver metastases of solid tumors of epithelial origin, or primary advanced hepatic carcinoma; and CBL0137, which is in multi-center, single agent, dose escalation Phase I study of the oral formulation in subjects with advanced solid tumors. In addition, it has pre-clinical stage products candidates, such as CBLB612, an inducer and mobilizer of hematopoietic stem cells; Revercom, a cancer drug candidate comprising a liposome-packaged proprietary small molecule named Reversan; Mobilan, a nanoparticle-formulated recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand, flagellin; Arkil, a prospective treatment for prostate cancer; Antimycon, a proprietary small molecule lead compound generated to selectively target and inactivate oncoproteins of the Myc family; and Xenomycin family of compounds, which have a range of potential applications as antimicrobial and anti-fungal agents. The company has license agreements and collaborations with the Cleveland Clinic, Roswell Park Cancer Institute, the Children's Cancer Institute Australia, and the Armed Forces Radiobiology Research Institute. Cleveland BioLabs, Inc. was founded in 2003 and is headquartered in Buffalo, New York.
Medicine Biotechnology Cancer Clinical Medicine Treatment Of Cancer Solid Tumors Chemotherapy Stem Cells Cancer Treatments Radiation Prostate Cancer Cancer Treatment Advanced Solid Tumors
Is CBLI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 2.16
52 Week Low 1.0
Average Volume 6,624
200-Day Moving Average 1.4874
50-Day Moving Average 1.3795
20-Day Moving Average 1.2652
10-Day Moving Average 1.126
Average True Range 0.0767
ADX 36.12
+DI 12.227
-DI 27.9261
Chandelier Exit (Long, 3 ATRs ) 1.2899
Chandelier Exit (Short, 3 ATRs ) 1.2401
Upper Bollinger Band 1.5762
Lower Bollinger Band 0.9542
Percent B (%b) 0.23
BandWidth 49.162188
MACD Line -0.102
MACD Signal Line -0.0802
MACD Histogram -0.0218
Fundamentals Value
Market Cap 12.41 Million
Num Shares 11.3 Million
EPS -0.67
Price-to-Earnings (P/E) Ratio -1.64
Price-to-Sales 12.32
Price-to-Book 7.79
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.21
Resistance 3 (R3) 1.19 1.15 1.19
Resistance 2 (R2) 1.15 1.12 1.15 1.18
Resistance 1 (R1) 1.12 1.10 1.14 1.14 1.18
Pivot Point 1.08 1.08 1.08 1.08 1.08
Support 1 (S1) 1.05 1.05 1.07 1.07 1.02
Support 2 (S2) 1.01 1.03 1.01 1.02
Support 3 (S3) 0.98 1.01 1.01
Support 4 (S4) 1.00